MiNK Therapeutics (INKT) has received formal notice from Nasdaq confirming that the company has regained compliance with both the minimum bid ...

The Kansas City Chiefs had their best outfits ready for Super Bowl LIX, and wide receiver DeAndre Hopkins' pregame attire ...

Abstract Title: Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory ...

Kansas City Chiefs wide receiver DeAndre Hopkins said he would wear his late father's mink coat to Super Bowl LIX.

Mink Ventures Corporation (TSXV:MINK) (“Mink” or the "Company") today announced that it has completed all share issuances and incurred all expenditures required to earn a 100% interest in the Warren ...

纽约 - 专注于开发iNKT细胞疗法用于治疗癌症和其他疾病的生物制药公司MiNK Therapeutics, Inc. (NASDAQ: INKT)宣布已重新符合纳斯达克的上市要求。该公司目前股价为$9.49，年初至今回报率达36%，尽管市值相对较小，为$37.64million，但展现出强劲的韧性。根据 InvestingPro ...

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of ...

Mink Ventures Corporation (TSXV:MINK) (“Mink” or the "Company") today announced assay results for its recently completed ...

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated ...

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of ...